DE60000665T2 - Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen - Google Patents

Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen

Info

Publication number
DE60000665T2
DE60000665T2 DE60000665T DE60000665T DE60000665T2 DE 60000665 T2 DE60000665 T2 DE 60000665T2 DE 60000665 T DE60000665 T DE 60000665T DE 60000665 T DE60000665 T DE 60000665T DE 60000665 T2 DE60000665 T2 DE 60000665T2
Authority
DE
Germany
Prior art keywords
virusfusion
long
viral infections
peptide inhibitors
body cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60000665T
Other languages
English (en)
Other versions
DE60000665T3 (de
DE60000665D1 (de
Inventor
Dominique P Bridon
Robert S Dufresne
Nissab Boudjellab
Martin Robitaille
Peter G Milner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CONJUCHEM BIOTECHNOLOGIES INC., MONTREAL, QUEBEC,
Original Assignee
ConjuChem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26832297&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60000665(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ConjuChem Inc filed Critical ConjuChem Inc
Publication of DE60000665D1 publication Critical patent/DE60000665D1/de
Application granted granted Critical
Publication of DE60000665T2 publication Critical patent/DE60000665T2/de
Publication of DE60000665T3 publication Critical patent/DE60000665T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DE60000665T 1999-05-17 2000-05-17 Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen Expired - Lifetime DE60000665T3 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13440699P 1999-05-17 1999-05-17
US134406P 1999-05-17
US15340699P 1999-09-10 1999-09-10
US153406P 1999-09-10
PCT/US2000/013651 WO2000069902A1 (en) 1999-05-17 2000-05-17 Long lasting fusion peptide inhibitors or viral infection

Publications (3)

Publication Number Publication Date
DE60000665D1 DE60000665D1 (de) 2002-11-28
DE60000665T2 true DE60000665T2 (de) 2003-06-26
DE60000665T3 DE60000665T3 (de) 2009-10-29

Family

ID=26832297

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60043021T Expired - Lifetime DE60043021D1 (de) 1999-05-17 2000-05-17 Lang wirkende Peptidinhibitoren der Virusfusion mit Körperzellen bei viralen Infektionen
DE60000665T Expired - Lifetime DE60000665T3 (de) 1999-05-17 2000-05-17 Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60043021T Expired - Lifetime DE60043021D1 (de) 1999-05-17 2000-05-17 Lang wirkende Peptidinhibitoren der Virusfusion mit Körperzellen bei viralen Infektionen

Country Status (14)

Country Link
US (4) US7582301B1 (de)
EP (3) EP1179012B2 (de)
JP (3) JP4216480B2 (de)
CN (1) CN1351611A (de)
AT (2) ATE226593T1 (de)
AU (1) AU761591B2 (de)
BR (1) BR0010757A (de)
CA (1) CA2372338A1 (de)
DE (2) DE60043021D1 (de)
DK (1) DK1264840T3 (de)
ES (2) ES2185595T5 (de)
HK (1) HK1053128A1 (de)
PT (1) PT1264840E (de)
WO (1) WO2000069902A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
DE60006100T2 (de) 1999-05-17 2004-07-01 Conjuchem, Inc., Montreal Lang wirkende insulinotrope peptide
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
WO2000069902A1 (en) 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting fusion peptide inhibitors or viral infection
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
PT1360202E (pt) 2001-02-16 2008-09-01 Conjuchem Biotechnologies Inc Peptídeo do tipo glucagon 2 (glp-2) de longa duração para o tratamento de doenças e distúrbios gastrointestinais
JP4463545B2 (ja) 2001-05-31 2010-05-19 コンジュケム バイオテクノロジーズ インコーポレイテッド Ｈｉｖ感染に対する長時間持続する融合ペプチドインヒビター
AU2002314111A1 (en) 2001-06-15 2003-01-02 F. Hoffmann-La Roche Ag Method for the recombinant production of peptidic antiviral fusion inhibitors, and acetylation of gb41 fragments
BR0314657A (pt) 2002-09-24 2005-08-02 Dong Xie Inibidores de fusão de derivados de peptìdeo de infecção de hiv
US7556813B2 (en) * 2002-09-27 2009-07-07 Trimeris, Inc. Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides
CA2443365C (en) * 2002-11-19 2010-01-12 F. Hoffmann-La Roche Ag Methods for the recombinant production of antifusogenic peptides
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
CA2543257C (en) 2003-10-24 2013-12-31 Gencia Corporation Methods and compositions for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
SI1745078T1 (sl) * 2004-04-23 2009-12-31 Conjuchem Biotechnologies Inc Postopek za äśiĺ äśenje albumin konjugatov
US7723063B2 (en) * 2004-04-28 2010-05-25 Intrinsic Lifesciences Methods for measuring levels of bioactive human hepcidin
AU2005240680A1 (en) * 2004-05-06 2005-11-17 Conjuchem Biotechnologies Inc. Compounds for specific viral target
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
CA2634495A1 (en) * 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
CN100475270C (zh) 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
US7456251B2 (en) 2006-02-02 2008-11-25 Trimeris, Inc. HIV fusion inhibitor peptides with improved biological properties
CN100366633C (zh) * 2006-04-18 2008-02-06 河北师范大学 棕点湍蛙抗病毒多肽及其在制药中的应用
CA2658474A1 (en) 2006-08-17 2008-02-21 F.Hoffmann-La Roche Ag A conjugate of an antibody against ccr5 and an antifusogenic peptide
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
US20090088378A1 (en) * 2007-01-12 2009-04-02 Omar Quraishi Long lasting inhibitors of viral infection
CL2008000707A1 (es) * 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
AU2008254767A1 (en) * 2007-05-16 2008-11-27 Conjuchem Biotechnologies Inc. Cysteic acid derivatives of anti-viral peptides
AR067584A1 (es) 2007-07-20 2009-10-14 Hoffmann La Roche Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicos
WO2009019314A1 (en) 2007-08-08 2009-02-12 Novozymes A/S Transferrin variants and conjugates
EP2036980A1 (de) * 2007-09-14 2009-03-18 Gruber, Jens Herabregulation der Genexpression mittels Nukleinsäure-beladener virusähnlicher Partikel
US20090186819A1 (en) * 2007-12-11 2009-07-23 Marieve Carrier Formulation of insulinotropic peptide conjugates
US9493545B2 (en) 2009-02-11 2016-11-15 Albumedix A/S Albumin variants and conjugates
KR101425405B1 (ko) * 2009-07-17 2014-08-01 한림대학교 산학협력단 리포좀에 포집된 올리고뉴클레오타이드 및 에피토프를 포함하는 면역증강용 조성물
JP2013509170A (ja) 2009-10-30 2013-03-14 ノボザイムス バイオファーマ デーコー アクティーゼルスカブ アルブミン変異体
CN102939304B (zh) 2010-04-09 2017-04-19 阿尔布麦狄克斯公司 白蛋白衍生物和变体
BR112013002292A2 (pt) 2010-09-14 2016-06-14 Hoffmann La Roche polipeptídeo du fusão, complexo de proteína, uso e kit
US20130225496A1 (en) 2010-11-01 2013-08-29 Novozymes Biopharma Dk A/S Albumin Variants
RU2650784C2 (ru) 2011-05-05 2018-04-17 Альбумедикс А/С Варианты альбумина
EP3384938A1 (de) 2011-09-12 2018-10-10 Moderna Therapeutics, Inc. Manipulierte nukleinsäuren und verfahren zur verwendung davon
EP2780364A2 (de) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteine mit verbesserter halbwertzeit und anderen eigenschaften
CN104736559B (zh) 2012-03-16 2022-04-08 阿尔布梅迪克斯医疗有限公司 白蛋白变体
WO2013151667A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides
AU2013243949A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
WO2013150532A1 (en) 2012-04-04 2013-10-10 Yeda Research And Development Co. Ltd. Lipopeptide conjugates comprising sphingolipid and hiv gp41 derived peptides
CN105452290A (zh) 2012-11-08 2016-03-30 诺维信生物制药丹麦公司 白蛋白变体
CN105007722A (zh) 2013-02-16 2015-10-28 诺维信生物制药丹麦公司 药代动力学动物模型
WO2014165452A1 (en) * 2013-04-03 2014-10-09 The Regents Of The University Of California Compositions and methods for inhibiting viral activity
EP3063171B1 (de) 2013-11-01 2019-07-24 University Of Oslo Albuminvarianten und verwendungen davon
CN103864921B (zh) * 2014-01-16 2017-12-26 苏州大学 双重靶向治疗癌症的叶酸‑阿霉素免疫制剂及其制备方法
US20170107294A1 (en) 2014-03-21 2017-04-20 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
WO2017029407A1 (en) 2015-08-20 2017-02-23 Albumedix A/S Albumin variants and conjugates
WO2017083515A2 (en) 2015-11-10 2017-05-18 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
US20210333279A1 (en) 2016-11-04 2021-10-28 Aarhus Universitet Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
EP3571223A1 (de) 2017-01-18 2019-11-27 Visterra, Inc. Antikörpermolekülarzneimittelkonjugate und verwendungen davon
CN111303245B (zh) * 2020-02-21 2023-06-27 成都奥达生物科技有限公司 一种抗合胞病毒膜融合抑制剂
AU2021248643A1 (en) 2020-04-03 2022-10-27 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
WO2021211303A1 (en) * 2020-04-14 2021-10-21 Contrafect Corporation Antiviral, bacteriophage-derived polypeptides and their use against viruses

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719667A (en) 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
US4652629A (en) * 1985-07-03 1987-03-24 The Salk Institute For Biological Studies Synthetic peptide-based anti-rabies compositions and methods
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
CA2106314A1 (en) 1991-04-05 1992-10-06 John P. Burnier Platelet aggregation inhibitors having high specification for gpiibiiia
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
ATE183515T1 (de) 1992-07-20 1999-09-15 Univ Duke Zusammensetzungen die die hiv replikation inhibieren
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
EP0602290B1 (de) 1992-12-04 1999-08-25 ConjuChem, Inc. Antikörper-konjugiertes-Hepatitis B-Oberflächenantigen und dessen Verwendung
US5614487A (en) 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6518013B1 (en) * 1993-06-07 2003-02-11 Trimeris, Inc. Methods for the inhibition of epstein-barr virus transmission employing anti-viral peptides capable of abrogating viral fusion and transmission
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6017536A (en) 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US6342225B1 (en) * 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
CA2220339C (en) 1995-05-10 2009-10-13 Kyowa Hakko Kogyo Co., Ltd. Toxin conjugates having a spacer comprising polyalkylene glycol and peptide
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
JP4086936B2 (ja) 1996-10-03 2008-05-14 株式会社ブリヂストン ダミーウェハ
US6150088A (en) * 1997-04-17 2000-11-21 Whitehead Institute For Biomedical Research Core structure of gp41 from the HIV envelope glycoprotein
DE69806066T2 (de) * 1997-11-07 2003-02-06 Conjuchem Inc Affinitätsmarkierer für menschliches serum albumin
EP1028971A2 (de) * 1997-11-07 2000-08-23 ConjuChem, Inc. Neue konjugate von rgd-enthaltenden peptiden und endogenen trägern
US6107489A (en) * 1998-03-17 2000-08-22 Conjuchem, Inc. Extended lifetimes in vivo renin inhibitors
WO1999048536A2 (en) * 1998-03-23 1999-09-30 Conjuchem, Inc. Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
ATE298796T1 (de) * 1998-10-13 2005-07-15 Univ Georgia Res Found Stabilisierte bioaktive peptide und methoden zu ihrer identifikation, synthese und verwendung
US20030190740A1 (en) * 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
WO2000069902A1 (en) 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting fusion peptide inhibitors or viral infection
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926475A1 (de) 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
US7090851B1 (en) 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
JP4463545B2 (ja) 2001-05-31 2010-05-19 コンジュケム バイオテクノロジーズ インコーポレイテッド Ｈｉｖ感染に対する長時間持続する融合ペプチドインヒビター
SI1745078T1 (sl) * 2004-04-23 2009-12-31 Conjuchem Biotechnologies Inc Postopek za äśiĺ äśenje albumin konjugatov
AU2005240680A1 (en) 2004-05-06 2005-11-17 Conjuchem Biotechnologies Inc. Compounds for specific viral target

Also Published As

Publication number Publication date
DE60043021D1 (de) 2009-11-05
ES2185595T5 (es) 2009-12-17
JP2008101021A (ja) 2008-05-01
ES2185595T3 (es) 2003-05-01
EP1264840A1 (de) 2002-12-11
AU761591B2 (en) 2003-06-05
JP4216480B2 (ja) 2009-01-28
PT1264840E (pt) 2010-01-04
EP1179012B2 (de) 2009-07-15
WO2000069902A1 (en) 2000-11-23
JP2002544287A (ja) 2002-12-24
HK1053128A1 (en) 2003-10-10
ES2334106T3 (es) 2010-03-05
ATE443714T1 (de) 2009-10-15
US20080176794A1 (en) 2008-07-24
EP1179012B9 (de) 2003-09-10
JP2009167208A (ja) 2009-07-30
DE60000665T3 (de) 2009-10-29
US7582301B1 (en) 2009-09-01
EP2110381A1 (de) 2009-10-21
CN1351611A (zh) 2002-05-29
EP1179012B1 (de) 2002-10-23
CA2372338A1 (en) 2000-11-23
EP1179012A1 (de) 2002-02-13
EP1264840B1 (de) 2009-09-23
DK1264840T3 (da) 2009-11-16
US20050070475A1 (en) 2005-03-31
DE60000665D1 (de) 2002-11-28
AU5027100A (en) 2000-12-05
US20080199483A1 (en) 2008-08-21
US7608271B2 (en) 2009-10-27
ATE226593T1 (de) 2002-11-15
BR0010757A (pt) 2002-02-19

Similar Documents

Publication Publication Date Title
DE60000665D1 (de) Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen
DK1180121T3 (da) Langtidsvirkende insulinotrope peptider
LU92175I2 (fr) Lixisénatide
EA200701386A1 (ru) Полиалкиленгликоль с остатком для конъюгации биологически активного соединения
FI933740A (fi) PEG-interferonkonjugat
CU23048A3 (es) Aminoacidos ciclicos y derivados de los mismos, utiles como agentes farmaceuticos
DK0633721T3 (da) Rensning af blodplader med 8-metoxypsoralen
DK0973819T3 (da) Ikke-antigene forgrenede polymerkonjugater
ATE425188T1 (de) Physiologisch wirksames polypeptidkonjugat mit verlängerter in vivo halbwertszeit
ATE263579T1 (de) Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel
PT88417A (pt) Stabilisierte humanprotein-praeparate
DK1025124T3 (da) Human interferon-alfa-analoge med lav toksicitet
DE69942231D1 (de) Ortspezifische duale pegylation von proteine
DE60331049D1 (de) Konjugate von zytotoxischen mitteln und biologisch aktiven peptiden
DE60010230D1 (de) Pharmazeutische zusammensetzung von hydrophob modifizierten hedgehog-proteinen und deren verwendung
DE69513632T2 (de) Mikrogranulate enthaltend 5-nitroimidazolderivate
TH52654A (th) แอนตี-แอนจิโอจินิก เปปไทด์ ที่มีอายุยาวนาน
ATE347899T1 (de) Interferon nachahmende peptide und rekombinante proteine

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: CONJUCHEM BIOTECHNOLOGIES INC., MONTREAL, QUEBEC,

8366 Restricted maintained after opposition proceedings